LUX-Head & Neck-1 trial with Afatinib Results #hncs16

Ezra Cohen, MD of the University of California at San Diego discusses the results of the LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy at ASTRO Head and Neck Symposium 2016.